 |
市場調查報告書
商品編碼
2075158
中和抗體市場：依抗體類型、標靶病毒、最終用途、通路和地區分類Neutralizing Antibody Market, By Antibody Type, By Target Virus, By End Use, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到2026年，中和抗體市場規模將達到2,654億美元，到2033年將達到4,789.6億美元。預計從2026年到2033年，其複合年成長率將達到8.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 2654億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 8.80% | 2033年市場規模預測： | 4789.6億美元 |
中和抗體是先天免疫的重要組成部分，可透過自然感染和疫苗接種誘導產生。這些抗體能夠辨識病毒上的特定位點，阻止病毒與細胞結合並感染細胞。由於抗體的特殊結構，它們能夠與病毒刺突蛋白上的受體結合域（RBD）結合，阻止病毒與宿主細胞上的受體結合並進入細胞。
市場動態：
全球中和抗體市場預計在預測期內將快速成長。推動這一成長的主要因素之一是肝炎、愛滋病和結核病等感染疾病的高發生率。多種治療性單株抗體（mAb）的出現也是促進市場成長的因素之一。此外，mAb研發先進技術的引進預計也將推動該市場的成長。然而，這些檢測的高昂成本可能會限制其應用，從而阻礙市場成長。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球中和抗體市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球中和抗體市場報告」旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球中和抗體市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 感染疾病的傳播
- 自體免疫疾病發生率增加
- 生物技術和單株抗體研發的進展
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特五力分析
- 併購情景
第4章 中和抗體市場：依抗體類型分類，2021-2026年
- 單株抗體
- 多株抗體
第5章 中和抗體市場：以標靶病毒分類，2021-2026年
- HIV
- 流感
- 伊波拉
- 茲卡
- C型肝炎
- 其他
第6章 中和抗體市場：依應用領域分類，2021-2026年
- 治療
- 診斷
- 研究與開發
第7章 中和抗體市場：依最終用戶分類，2021-2026年
- 醫院和診所
- 研究機構
- 診斷檢查室
- 製藥公司
- 其他
第8章 中和抗體市場：依通路分類，2021-2026年
- 直接銷售給最終用戶
- 銷售代理
- 線上零售
- 其他
第9章 中和抗體市場：依地區分類，2021-2026年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 中東和非洲
- GCC
- 以色列
- 北非
- 中非
- 其他中東和非洲國家
第10章 競爭格局
- Regeneron Pharmaceuticals, Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Sanofi SA
- Roche Holding AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- Moderna, Inc.
- BioNTech SE
- CSL Limited
- Sinovac Biotech Ltd.
第11章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5898
Neutralizing Antibody Market is estimated to be valued at USD 265.40 Bn in 2026 and is expected to reach USD 478.96 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 265.40 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.80% | 2033 Value Projection: | USD 478.96 Bn |
Neutralizing antibodies are a critical component of natural immunity and can be induced by both natural infection and vaccination. These antibodies recognize specific parts of the virus and prevent them from binding to and infecting cells. The antibodies' specialized structure allows them to bind to the receptor binding domain (RBD) on the viral spike protein, preventing it from engaging the host cell's receptor and facilitating virus entry into the cell.
Market Dynamics:
The global neutralizing antibody market is expected grow rapidly over the forecast period. One of the key drivers for this growth is the high prevalence of infectious diseases such as hepatitis, HIV, and tuberculosis. The availability of several therapeutic mAbs is another factor driving market growth. In addition, the introduction of advanced technologies for developing mAbs is expected to drive the growth of this market. However, the high cost of these tests can limit their adoption, thereby hindering market growth.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neutralizing antibody market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, AstraZeneca PLC, GlaxoSmithKline plc, Sanofi SA, Roche Holding AG, Novartis AG, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Takeda, Pharmaceutical Company Limited, Moderna, Inc., BioNTech SE, CSL Limited, and Sinovac Biotech Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neutralizing antibody market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neutralizing antibody market
Neutralizing Antibody Market Detailed Segmentation:
- By Antibody Type (Revenue, USD Bn, 2021 - 2033):
- Monoclonal Antibodies
- Polyclonal Antibodies
- By Target Virus (Revenue, USD Bn, 2021 - 2033):
- SARS-CoV-2 (COVID-19)
- HIV
- Influenza
- Ebola
- Zika
- Hepatitis C
- Others
- By Application (Revenue, USD Bn, 2021 - 2033):
- Therapeutics
- Diagnostics
- Research and Development
- By End User (Revenue, USD Bn, 2021 - 2033):
- Hospitals and Clinics
- Research Institutes
- Diagnostic Laboratories
- Pharmaceutical Companies
- Others
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033):
- Direct Sales to End-Users
- Distributors
- Online Retail
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players
- Regeneron Pharmaceuticals, Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Sanofi SA
- Roche Holding AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- Moderna, Inc.
- BioNTech SE
- CSL Limited
- Sinovac Biotech Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Neutralizing Antibody, By Antibody Type
- Market Neutralizing Antibody, By Target Virus
- Market Neutralizing Antibody, By Application
- Market Neutralizing Antibody, By End User
- Market Neutralizing Antibody, By Distribution Channel
- Market Neutralizing Antibody, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Infectious Diseases
- Rising Incidence of Autoimmune Disorders
- Advancements in Biotechnology and Monoclonal Antibody Development
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Neutralizing Antibody Market , By Antibody Type, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Bn)
- Polyclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Bn)
5. Neutralizing Antibody Market , By Target Virus, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- HIV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Influenza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Ebola
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Zika
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
6. Neutralizing Antibody Market , By Application, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Research and Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
7. Neutralizing Antibody Market , By End User, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
8. Neutralizing Antibody Market , By Distribution Channel, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Direct Sales to End-Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Distributors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Online Retail
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2026,(US$ Billion)
9. Neutralizing Antibody Market , By Region, 2021-2026, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 €"2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2026,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2026,(US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2026,(US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2026,(US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2026,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2026,(US$ Bn)
- GCC
- Israel
- North Africa
- Central Africa
- Rest of Middle East & Africa
10. Competitive Landscape
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sinovac Biotech Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
